Skip to main
KZR
KZR logo

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences Inc. has seen increased investor confidence following the partial lifting of the clinical hold in autoimmune hemolytic anemia (AIH), indicating a positive risk-benefit profile for its lead therapeutic candidate, Zetomipzomib (KZR-616). The full removal of the clinical hold for lupus nephritis (LN) would significantly enhance this confidence and further stimulate potential clinical uptake, signaling a promising trajectory for the company’s development pipeline. Additionally, if the clinical hold in LN is lifted, it may lead to resumed development efforts, thereby broadening the commercial opportunities for Kezar's assets.

Bears say

Kezar Life Sciences Inc. has reported ongoing challenges in the execution of its clinical trials, which may potentially delay the development of its key product candidates, Zetomipzomib (KZR-616) and KZR-261. The company has also experienced increased operational costs, leading to a significant operating loss that raises concerns about its financial sustainability and ability to fund research and development in the long term. Furthermore, the lack of significant partnerships or collaborations to bolster its financial position casts doubt on its capability to navigate the competitive landscape of biotechnology effectively.

KZR has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 1 analysts, KZR has a Hold consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.